Optical diagnostics company MediBeacon was just issued another patent, the company has a score of them. This latest patent covers compositions and methods for assessing gut function.
The company uses novel light-activated agents for a number of medical applications. Right now they have a noninvasive real-time kidney function monitoring system that is in human clinical trials.
Founded in 2011 MediBeacon has brought in $83.3 million in venture capital (according to CrunchBase). This week’s gut function assessment patent will be used in MediBeacon’s trans-dermal systems, which have the goal of providing clinically practical gastrointestinal permeability assessment.
Online:
